BBIOBridgeBio Pharma, Inc.

1. Aug 31, 2026The Company expects its pricing commitment for its future medicines under its agreement with the U.S. government to exclude medicines approved exclusively for orphan indications.Other event · Form 8-K
2. Aug 17, 2026On August 13, 2026, BridgeBio Pharma, Inc. (the “Company”) and KKR Genetic Disorder L.P. (the “Selling Stockholder”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as the representatives of the several …Material agreement entered · Form 8-K
3. Aug 10, 2026BridgeBio Reports Second Quarter 2026.Earnings release · press release
4. Jul 22, 2026BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1.Other event · press release
5. Jul 2, 2026Investment Agreement and Preferred Stock Terms On July 1, 2026 (the “Closing Date”), BridgeBio Pharma, Inc. (the “Company”) entered into an Investment Agreement (the “Investment Agreement”) with the purchasers identified therein (collectively, the “Purchasers”), including Chinotto Investments, LLC (the “Sixth Street …Material agreement entered · Form 8-K
6. Jun 26, 2026On June 22, 2026, Dr. Randal W. Scott notified BridgeBio Pharma, Inc. (the “Company”), of his resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of his term as a Class I director, effective as of June 22, 2026, the date of the Company’s 2026 Annual Meeting of …Director or officer change · Form 8-K
7. May 8, 2026On May 7, 2026, BridgeBio Pharma, Inc. (the “Company”) filed a registration statement on Form S-3ASR (File No.: 333-295678, the “Registration Statement”) under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”) with the Securities and Exchange Commission. In addition, on May 7, 2026, the …Material agreement entered · Form 8-K
8. May 7, 2026On May 6, 2026, the Board of Directors of the Company approved a stock repurchase program pursuant to which the Company may purchase up to $500 million of the Company’s outstanding common stock.Earnings release · Form 8-K
9. Mar 30, 2026BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9.Other event · press release
10. Feb 24, 2026BridgeBio Reports Fourth Quarter and.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.